Hanumunthadu, Brama, Kanji, Nasir, Owino, Nelly, Ferreira Da Silva, Carla, Robinson, Hannah, White, Rachel, Ferruzzi, Pietro, Nakakana, Usman, Canals, Rocio, Pollard, Andrew J et al (show 2 more authors)
(2023)
<i>Salmonella</i> Vaccine Study in Oxford (SALVO) trial: protocol for an observer-participant blind randomised placebo-controlled trial of the iNTS-GMMA vaccine within a European cohort.
BMJ open, 13 (11).
e072938-e072938.
Abstract
<h4>Introduction</h4>Invasive non-typhoidal Salmonellosis (iNTS) is mainly caused by <i>Salmonella enterica</i> serovars Typhimurium and Enteritidis and is estimated to result in 77 500 deaths per year, disproportionately affecting children under 5 years of age in sub-Saharan Africa. Invasive non-typhoidal <i>Salmonellae</i> serovars are increasingly acquiring resistance to first-line antibiotics, thus an effective vaccine would be a valuable tool in reducing morbidity and mortality from infection. While NTS livestock vaccines are in wide use, no licensed vaccines exist for use in humans. Here, a first-in-human study of a novel vaccine (iNTS-GMMA) containing <i>S</i>. Typhimurium and <i>S</i>. Enteritidis Generalised Modules for Membrane Antigens (GMMA) outer membrane vesicles is presented.<h4>Method and analysis</h4>The <i>Salmonella</i> Vaccine Study in Oxford is a randomised placebo-controlled participant-observer blind phase I study of the iNTS-GMMA vaccine. Healthy adult volunteers will be randomised to receive three intramuscular injections of the iNTS-GMMA vaccine, containing equal quantities of <i>S</i>. Typhimurium and <i>S</i>. Enteritidis GMMA particles adsorbed on Alhydrogel, or an Alhydrogel placebo at 0, 2 and 6 months. Participants will be sequentially enrolled into three groups: group 1, 1:1 randomisation to low dose iNTS-GMMA vaccine or placebo; group 2, 1:1 randomisation to full dose iNTS-GMMA vaccine or placebo; group 3, 2:1 randomisation to full dose or lower dose (dependant on DSMC reviews of groups 1 and 2) iNTS-GMMA vaccine or placebo.The primary objective is safety and tolerability of the vaccine. The secondary objective is immunogenicity as measured by O-antigen based ELISA. Further exploratory objectives will characterise the expanded human immune profile.<h4>Ethics and dissemination</h4>Ethical approval for this study has been obtained from the South Central-Oxford A Research Ethics Committee (Ethics REF:22/SC/0059). Appropriate documentation and regulatory approvals have been acquired. Results will be disseminated via peer-reviewed articles and conferences.<h4>Trial registration number</h4>EudraCT Number: 2020-000510-14.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Vacc-iNTS Consortium |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Infection, Veterinary and Ecological Sciences |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 09 Apr 2024 08:33 |
| Last Modified: | 09 Apr 2024 13:15 |
| DOI: | 10.1136/bmjopen-2023-072938 |
| Open Access URL: | https://bmjopen.bmj.com/content/13/11/e072938 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3180154 |
Dimensions
Dimensions
